

Global Decentralised Clinical Trials Market Size Study, by Study Design (Interventional, Observational, Expanded Access), by Indication (Oncology, Cardiovascular, Immunology, Respiratory, Others), by Component (Mobile Healthcare, Telemedicine, Wearable Devices, Web-based Technology, Others), by End-users (Pharmaceutical and Biopharmaceutical Companies, CROs, Others) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G95651D9E31AEN.html

Date: July 2024 Pages: 200 Price: US\$ 4,950.00 (Single User License) ID: G95651D9E31AEN

Abstracts

Global Decentralised Clinical Trials Market is valued at approximately USD 9.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.40% over the forecast period 2024-2032. Decentralised Clinical Trials (DCTs) has revolutionized the landscape of clinical research, offering a paradigm shift in how trials are conducted. This innovative approach leverages digital health technologies, enabling remote monitoring and data collection, thus enhancing participant convenience and broadening patient diversity. The driving force behind this market surge includes the imperative to accelerate drug development timelines, mitigate costs, and increase the accessibility of diverse treatments to among large number of patients.

The globalization of clinical trials underscores a transformative era in the healthcare sector, driven by an extensive reach across various geographies. Pharmaceutical and biotech companies are heavily investing in these trials to garner comprehensive data from diverse demographic groups. This inclusivity in clinical trials fosters a deeper understanding of treatment efficacies across different genetic and socio-economic backgrounds, unveiling critical insights into potential side effects and drug responses.



Moreover, regulatory harmonization has streamlined approval processes across multiple countries, reducing redundant efforts and expediting the introduction of breakthrough therapies to the market. However, concerns regarding data privacy and security and regulatory compliance are going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the Global Decentralised Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the dominating among regional market in terms of revenue owing to factors such as advanced healthcare infrastructure and the presence of major pharmaceutical companies. Regulatory bodies such as the FDA have been increasingly supportive of DCTs, providing guidelines and frameworks that facilitate the adoption of these trials. This regulatory environment encourages pharmaceutical companies to explore decentralized models. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.

Major market players included in this report are:

ICON plc

Medpace Holdings, Inc.

Parexel International Corporation

PPD, Inc.

Covance Inc.

LabCorp Drug Development

PRA Health Sciences

Syneos Health

IQVIA Holdings Inc.

Charles River Laboratories International, Inc

The detailed segments and sub-segment of the market are explained below:



By Study Design

Interventional

Observational

Expanded Access

By Indication

Oncology

Cardiovascular

Immunology

Respiratory

Others

By Component

Mobile Healthcare

Telemedicine

Wearable Devices

Web-based Technology

Others

By End-users

Pharmaceutical and Biopharmaceutical Companies

CROs



By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America



Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year - 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market



Contents

CHAPTER 1. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET EXECUTIVE SUMMARY

- 1.1. Global Decentralised Clinical Trials Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Study Design
- 1.3.2. By Indication
- 1.3.3. By Component
- 1.3.4. By End-users
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates



CHAPTER 3. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET DYNAMICS

- 3.1. Market Drivers
 - 3.1.1. Accelerated Drug Development
 - 3.1.2. Cost Reduction
 - 3.1.3. Access to Diverse Populations
- 3.2. Market Challenges
 - 3.2.1. Data Privacy and Security Concerns
 - 3.2.2. Regulatory Compliance
- 3.3. Market Opportunities
 - 3.3.1. Technological Advancements
 - 3.3.2. Expansion in Emerging Markets
 - 3.3.3. Increased Collaboration and Data Exchange

CHAPTER 4. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
 - 4.1.6. Futuristic Approach to Porter's 5 Force Model
 - 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economical
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE &



FORECASTS BY STUDY DESIGN 2022-2032

5.1. Segment Dashboard

5.2. Global Decentralised Clinical Trials Market: Study Design Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 5.2.1. Interventional
- 5.2.2. Observational
- 5.2.3. Expanded Access

CHAPTER 6. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY INDICATION 2022-2032

6.1. Segment Dashboard

6.2. Global Decentralised Clinical Trials Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 6.2.1. Oncology
- 6.2.2. Cardiovascular
- 6.2.3. Immunology
- 6.2.4. Respiratory
- 6.2.5. Others

CHAPTER 7. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY COMPONENT 2022-2032

7.1. Segment Dashboard

7.2. Global Decentralised Clinical Trials Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 7.2.1. Mobile Healthcare
- 7.2.2. Telemedicine
- 7.2.3. Wearable Devices
- 7.2.4. Web-based Technology
- 7.2.5. Others

CHAPTER 8. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY END-USERS 2022-2032

8.1. Segment Dashboard

8.2. Global Decentralised Clinical Trials Market: End-users Revenue Trend Analysis, 2022 & 2032 (USD Billion)



- 8.2.1. Pharmaceutical and Biopharmaceutical Companies
- 8.2.2. CROs
- 8.2.3. Others

CHAPTER 9. GLOBAL DECENTRALISED CLINICAL TRIALS MARKET SIZE & FORECASTS BY REGION 2022-2032

9.1. North America Decentralised Clinical Trials Market 9.1.1. U.S. Decentralised Clinical Trials Market 9.1.1.1. Study Design breakdown size & forecasts, 2022-2032 9.1.1.2. Indication breakdown size & forecasts, 2022-2032 9.1.1.3. Component breakdown size & forecasts, 2022-2032 9.1.1.4. End-users breakdown size & forecasts, 2022-2032 9.1.2. Canada Decentralised Clinical Trials Market 9.1.2.1. Study Design breakdown size & forecasts, 2022-2032 9.1.2.2. Indication breakdown size & forecasts, 2022-2032 9.1.2.3. Component breakdown size & forecasts, 2022-2032 9.1.2.4. End-users breakdown size & forecasts, 2022-2032 9.2. Europe Decentralised Clinical Trials Market 9.2.1. U.K. Decentralised Clinical Trials Market 9.2.1.1. Study Design breakdown size & forecasts, 2022-2032 9.2.1.2. Indication breakdown size & forecasts, 2022-2032 9.2.1.3. Component breakdown size & forecasts, 2022-2032 9.2.1.4. End-users breakdown size & forecasts, 2022-2032 9.2.2. Germany Decentralised Clinical Trials Market 9.2.2.1. Study Design breakdown size & forecasts, 2022-2032 9.2.2.2. Indication breakdown size & forecasts, 2022-2032 9.2.2.3. Component breakdown size & forecasts, 2022-2032 9.2.2.4. End-users breakdown size & forecasts, 2022-2032 9.2.3. France Decentralised Clinical Trials Market 9.2.3.1. Study Design breakdown size & forecasts, 2022-2032 9.2.3.2. Indication breakdown size & forecasts, 2022-2032 9.2.3.3. Component breakdown size & forecasts, 2022-2032 9.2.3.4. End-users breakdown size & forecasts, 2022-2032 9.2.4. Spain Decentralised Clinical Trials Market 9.2.4.1. Study Design breakdown size & forecasts, 2022-2032 9.2.4.2. Indication breakdown size & forecasts, 2022-2032 9.2.4.3. Component breakdown size & forecasts, 2022-2032 9.2.4.4. End-users breakdown size & forecasts, 2022-2032



9.2.5. Italy Decentralised Clinical Trials Market 9.2.5.1. Study Design breakdown size & forecasts, 2022-2032 9.2.5.2. Indication breakdown size & forecasts, 2022-2032 9.2.5.3. Component breakdown size & forecasts, 2022-2032 9.2.5.4. End-users breakdown size & forecasts, 2022-2032 9.2.6. Rest of Europe Decentralised Clinical Trials Market 9.2.6.1. Study Design breakdown size & forecasts, 2022-2032 9.2.6.2. Indication breakdown size & forecasts, 2022-2032 9.2.6.3. Component breakdown size & forecasts, 2022-2032 9.2.6.4. End-users breakdown size & forecasts, 2022-2032 9.3. Asia-Pacific Decentralised Clinical Trials Market 9.3.1. China Decentralised Clinical Trials Market 9.3.1.1. Study Design breakdown size & forecasts, 2022-2032 9.3.1.2. Indication breakdown size & forecasts, 2022-2032 9.3.1.3. Component breakdown size & forecasts, 2022-2032 9.3.1.4. End-users breakdown size & forecasts, 2022-2032 9.3.2. India Decentralised Clinical Trials Market 9.3.2.1. Study Design breakdown size & forecasts, 2022-2032 9.3.2.2. Indication breakdown size & forecasts, 2022-2032 9.3.2.3. Component breakdown size & forecasts, 2022-2032 9.3.2.4. End-users breakdown size & forecasts, 2022-2032 9.3.3. Japan Decentralised Clinical Trials Market 9.3.3.1. Study Design breakdown size & forecasts, 2022-2032 9.3.3.2. Indication breakdown size & forecasts, 2022-2032 9.3.3.3. Component breakdown size & forecasts, 2022-2032 9.3.3.4. End-users breakdown size & forecasts, 2022-2032 9.3.4. Australia Decentralised Clinical Trials Market 9.3.4.1. Study Design breakdown size & forecasts, 2022-2032 9.3.4.2. Indication breakdown size & forecasts, 2022-2032 9.3.4.3. Component breakdown size & forecasts, 2022-2032 9.3.4.4. End-users breakdown size & forecasts, 2022-2032 9.3.5. South Korea Decentralised Clinical Trials Market 9.3.5.1. Study Design breakdown size & forecasts, 2022-2032 9.3.5.2. Indication breakdown size & forecasts, 2022-2032 9.3.5.3. Component breakdown size & forecasts, 2022-2032 9.3.5.4. End-users breakdown size & forecasts, 2022-2032 9.3.6. Rest of Asia Pacific Decentralised Clinical Trials Market 9.3.6.1. Study Design breakdown size & forecasts, 2022-2032 9.3.6.2. Indication breakdown size & forecasts, 2022-2032



9.3.6.3. Component breakdown size & forecasts, 2022-2032 9.3.6.4. End-users breakdown size & forecasts, 2022-2032 9.4. Latin America Decentralised Clinical Trials Market 9.4.1. Brazil Decentralised Clinical Trials Market 9.4.1.1. Study Design breakdown size & forecasts, 2022-2032 9.4.1.2. Indication breakdown size & forecasts, 2022-2032 9.4.1.3. Component breakdown size & forecasts, 2022-2032 9.4.1.4. End-users breakdown size & forecasts, 2022-2032 9.4.2. Mexico Decentralised Clinical Trials Market 9.4.2.1. Study Design breakdown size & forecasts, 2022-2032 9.4.2.2. Indication breakdown size & forecasts, 2022-2032 9.4.2.3. Component breakdown size & forecasts, 2022-2032 9.4.2.4. End-users breakdown size & forecasts, 2022-2032 9.4.3. Rest of Latin America Decentralised Clinical Trials Market 9.4.3.1. Study Design breakdown size & forecasts, 2022-2032 9.4.3.2. Indication breakdown size & forecasts, 2022-2032 9.4.3.3. Component breakdown size & forecasts, 2022-2032 9.4.3.4. End-users breakdown size & forecasts, 2022-2032 9.5. Middle East & Africa Decentralised Clinical Trials Market 9.5.1. Saudi Arabia Decentralised Clinical Trials Market 9.5.1.1. Study Design breakdown size & forecasts, 2022-2032 9.5.1.2. Indication breakdown size & forecasts, 2022-2032 9.5.1.3. Component breakdown size & forecasts, 2022-2032 9.5.1.4. End-users breakdown size & forecasts, 2022-2032 9.5.2. South Africa Decentralised Clinical Trials Market 9.5.2.1. Study Design breakdown size & forecasts, 2022-2032 9.5.2.2. Indication breakdown size & forecasts, 2022-2032 9.5.2.3. Component breakdown size & forecasts, 2022-2032 9.5.2.4. End-users breakdown size & forecasts. 2022-2032 9.5.3. Rest of Middle East & Africa Decentralised Clinical Trials Market 9.5.3.1. Study Design breakdown size & forecasts, 2022-2032 9.5.3.2. Indication breakdown size & forecasts, 2022-2032 9.5.3.3. Component breakdown size & forecasts, 2022-2032 9.5.3.4. End-users breakdown size & forecasts, 2022-2032

CHAPTER 10. COMPETITIVE INTELLIGENCE

10.1. Key Company SWOT Analysis

10.1.1. Company



- 10.1.2. Company
- 10.1.3. Company
- 10.2. Top Market Strategies
- 10.3. Company Profiles
 - 10.3.1. ICON plc
 - 10.3.1.1. Key Information
 - 10.3.1.2. Overview
 - 10.3.1.3. Financial (Subject to Data Availability)
 - 10.3.1.4. Product Summary
 - 10.3.1.5. Market Strategies
 - 10.3.2. Medpace Holdings, Inc.
 - 10.3.3. Parexel International Corporation
 - 10.3.4. PPD, Inc.
 - 10.3.5. Covance Inc.
 - 10.3.6. LabCorp Drug Development
 - 10.3.7. PRA Health Sciences
 - 10.3.8. Syneos Health
 - 10.3.9. IQVIA Holdings Inc.
 - 10.3.10. Charles River Laboratories International, Inc.

CHAPTER 11. RESEARCH PROCESS

- 11.1. Research Process
 - 11.1.1. Data Mining
 - 11.1.2. Analysis
 - 11.1.3. Market Estimation
 - 11.1.4. Validation
 - 11.1.5. Publishing
- 11.2. Research Attributes



List Of Tables

LIST OF TABLES

TABLE 1. Global Decentralised Clinical Trials Market, Report Scope TABLE 2. Global Decentralised Clinical Trials Market Estimates & Forecasts by Region 2022-2032 (USD Billion) TABLE 3. Global Decentralised Clinical Trials Market Estimates & Forecasts by Study Design 2022-2032 (USD Billion) TABLE 4. Global Decentralised Clinical Trials Market Estimates & Forecasts by Indication 2022-2032 (USD Billion) TABLE 5. Global Decentralised Clinical Trials Market Estimates & Forecasts by Component 2022-2032 (USD Billion) TABLE 6. Global Decentralised Clinical Trials Market Estimates & Forecasts by Endusers 2022-2032 (USD Billion) TABLE 7. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 8. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 9. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 10. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 11. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 12. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 13. Global Decentralised Clinical Trials Market by Segment, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 14. Global Decentralised Clinical Trials Market by Region, Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 15. U.S. Decentralised Clinical Trials Market Estimates & Forecasts, 2022-2032 (USD Billion) TABLE 16. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion) TABLE 17. U.S. Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion) TABLE 18. Canada Decentralised Clinical Trials Market Estimates & Forecasts. 2022-2032 (USD Billion)



TABLE 19. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)

TABLE 20. Canada Decentralised Clinical Trials Market Estimates & Forecasts by Segment 2022-2032 (USD Billion)

.

This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable



List Of Figures

LIST OF FIGURES

- FIG 1. Global Decentralised Clinical Trials Market, Research Methodology
- FIG 2. Global Decentralised Clinical Trials Market, Market Estimation Techniques
- FIG 3. Global Market Size Estimates & Forecast Methods.
- FIG 4. Global Decentralised Clinical Trials Market, Key Trends 2023
- FIG 5. Global Decentralised Clinical Trials Market, Growth Prospects 2022-2032
- FIG 6. Global Decentralised Clinical Trials Market, Porter's 5 Force Model
- FIG 7. Global Decentralised Clinical Trials Market, PESTEL Analysis
- FIG 8. Global Decentralised Clinical Trials Market, Value Chain Analysis
- FIG 9. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
- FIG 10. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
- FIG 11. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
- FIG 12. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
- FIG 13. Global Decentralised Clinical Trials Market by Segment, 2022 & 2032 (USD Billion)
- FIG 14. Global Decentralised Clinical Trials Market, Regional Snapshot 2022 & 2032
- FIG 15. North America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
- FIG 16. Europe Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
- FIG 17. Asia Pacific Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
- FIG 18. Latin America Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
- FIG 19. Middle East & Africa Decentralised Clinical Trials Market 2022 & 2032 (USD Billion)
- FIG 20. Global Decentralised Clinical Trials Market, Company Market Share Analysis (2023)



I would like to order

Product name: Global Decentralised Clinical Trials Market Size Study, by Study Design (Interventional, Observational, Expanded Access), by Indication (Oncology, Cardiovascular, Immunology, Respiratory, Others), by Component (Mobile Healthcare, Telemedicine, Wearable Devices, Web-based Technology, Others), by End-users (Pharmaceutical and Biopharmaceutical Companies, CROs, Others) and Regional Forecasts 2022-2032
Product link: https://marketpublishers.com/r/G95651D9E31AEN.html
Price: US\$ 4,950.00 (Single User License / Electronic Delivery)
If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G95651D9E31AEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970